@article{oai:niigata-u.repo.nii.ac.jp:00006372, author = {Itoh, Eiichi and Oda, Hirotaka and Miida, Tsutomu and Toeda, Tetsurou and Higuma, Norio}, issue = {3}, journal = {Acta medica et biologica, Acta medica et biologica}, month = {Sep}, note = {This study was done to determine the correlates of restenosis after deployment of the PalmazSchatz stent. Clinical, procedural and quantitative angiographic data from 85 consecutive patients (92 lesions) with successful stent deployment (diameter stenosis <50%) were analyzed. All patients had follow-up angiography 6.5±2.5 months after stenting. Minimal luminal diameters and diameter stenosis before and immediately after the procedure were 0.82±0.35 mm, 67.8±11.5% and 2.96±2.16mm, 0.9±19.3%. The number of deployed stents was 1.1 ±0.4. At follow-up, minimal luminal diameter was 1.93±0.75 mm and diameter stenosis was 23.4±27.6%. Restenosis (diameter stenosis≧50%)occurred in 16 (17.4%) lesions. The incidence of diabetes was significantly higher in the restenosis group than non-restenosis group (62.5% vs. 19.7%; p=0.0005), and lesion length was longer (16.2± 9.2 mm vs. 10.0±6.2 mm; p=0.0077). Other variables did not show differences between the two groups. Using logistic regression analysis, a multivariate study showed that restenosis was correlated only with diabetes (p < 0.0001, RR=18.18, 95%CI=3.38-97.68). In diabetic patients, HbAlc was higher in the restenosis group than the non-restenosis group at the time of stent deployment (7.6±0.7% vs. 6.3±1.4%; p=0.0484). Conclusion: Restenosis after the Palmaz-Schatz stent is strongly concerned with diabetes mellitus.}, pages = {101--107}, title = {Correlates of Restenosis after Deployment of the PalmazSchatz Stent: The Importance of Diabetes Mellitus in Patients with Coronary Artery Disease}, volume = {46}, year = {1998} }